A Phase 2 interventional study of SHR-1819 injection in Moderate to Severe Atopic Dermatitis, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 10th largest by enrollment, is the only one that started in 2023, is one of 6 in phase 2, and was the 6th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 12–17
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4
First in 2019; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is close to the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 159 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shanghai Hengrui Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.
3 of the studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07309055Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | 2027-11 |
| NCT07698756Chengdu Suncadia Medicine Co., Ltd.A Clinical Study of HRS-8797 in Healthy Participants | 2026-12 |
| NCT07321951Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of SHR-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously participated in the SHR-1819 injection study for atopic dermatitis (defined as the main study, referred to as the main study hereinafter).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-1819 injection
SHR-1819 injection 300 mg Q2W
Treatment Emergent Adverse Events (TEAEs) (per person-year)
Time frame: Up to 60 weeks
Serious Adverse Event (SAE) during treatment (per person-year)
Time frame: Up to 60 weeks
Adverse Events of Special Interest (AESI) during treatment (per person-year)
Time frame: Up to 60 weeks
Proportion of participants with a Global Assessment (IGA) score of 0 or 1 (0-4 scale) per visit
Time frame: Up to 60 weeks
Time to first remission (remission defined as IGA = 1 or 0 after treatment) in this study (for participants visiting 2 baseline IGAs ≥2)
Time frame: Up to 60 weeks
Proportion of participants with at least 1 remission in this study
Time frame: Up to 60 weeks
Time to first relapse in this study (relapse defined as IGA = 3 or 4 points after remission) (for participants with Visit 2 baseline IGA ≥ 2)
Time frame: Up to 60 weeks
The concentration of SHR-1819 in serum :Cmax
Time frame: From the beginning of administration to the 60h week
Immunogenic endpoint: evaluate the incidence and timing of ADA positivity for SHR-1819
Time frame: From the beginning of administration to the 60th week
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Jun 2025, 20 months.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 20 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Drotokibart
Shanghai Hengrui Pharmaceutical Co., Ltd. →